Advancedadvanced biology
The Proteasome: Controlled Protein Destruction
Learning objectives
- Describe the 26S architecture: 20S core particle and 19S regulatory particles.
- Explain how ubiquitin chains target substrates to the proteasome.
- Trace substrate processing: recognition, deubiquitination, unfolding, translocation.
- Evaluate the roles of proteasomal deubiquitinases as proofreading checkpoints.
- Relate proteasome function to ERAD, antigen presentation, and therapeutics.
Architecture of a demolition machine
The 26S proteasome is a ~2.5 megadalton complex built like a barrel with gated caps. The 20S core particle is a stack of four heptameric rings -- alpha, beta, beta, alpha -- forming a hollow cylinder. The outer alpha rings are gates, normally closed; the inner beta rings house the proteolytic active sites, which use N-terminal threonine residues to cleave after hydrophobic, basic, and acidic residues (the chymotrypsin-like, trypsin-like, and caspase-like activities). Capping one or both ends is the 19S regulatory particle, itself divided into a base containing six AAA+ ATPases arranged in a ring plus ubiquitin receptors, and a lid containing deubiquitinating enzymes. This architecture solves a fundamental problem: indiscriminate proteases would destroy the cell, so the active sites are sequestered inside a chamber whose narrow entry admits only unfolded polypeptides -- destruction by invitation only, with unfolding as the price of admission.
Ubiquitin: the admission ticket
Substrates earn entry by being tagged with ubiquitin chains -- most canonically, chains linked through ubiquitin's lysine 48, which the 19S ubiquitin receptors (Rpn10, Rpn13) recognize. But recognition is only the first checkpoint. The 19S base's ATPases grip the substrate and begin pulling, while the lid's deubiquitinases -- Rpn11 foremost -- strip the ubiquitin chain off, recycling ubiquitin and committing the substrate: a protein that cannot be unfolded is released rather than degraded, because deubiquitination is coupled to engagement. The ATPases then unfold the substrate mechanically, threading it through the narrow alpha-ring gate into the 20S chamber -- a remarkable feat, since they must unravel even stably folded domains, working against the protein's own folding energy with ATP hydrolysis. Inside the chamber, the polypeptide is cleaved processively into peptides typically under a dozen residues, which exit and are trimmed by cytosolic peptidases into amino acids for reuse.
Proofreading at the gate
The proteasome does not blindly shred everything ubiquitinated -- its deubiquitinases provide kinetic proofreading. Rpn11 removes the chain en bloc as the substrate is translocated, but two other DUBs, USP14 and UCH37, trim chains from the distal end and can rescue substrates: by shortening the chain before commitment, they give a marginally tagged or hard-to-unfold protein a chance to escape. USP14 in particular acts as a timer -- it must be outpaced by the ATPases' unfolding for degradation to proceed. This creates a selectivity filter beyond ubiquitination itself: chain length, linkage type, and the substrate's unfoldability all influence the outcome. The system also edits mistakes: accidentally ubiquitinated proteins with short chains are preferentially rescued, while properly targeted substrates with long K48 chains are committed. Inhibitors of proteasomal DUBs are now explored as drugs precisely because they shift this proofreading balance -- blocking USP14, for instance, accelerates degradation of some substrates.
ERAD, immunity, and the immunoproteasome
The proteasome serves specialized circuits. In ER-associated degradation (ERAD), misfolded secretory proteins are detected in the endoplasmic reticulum, retrotranslocated through channels into the cytosol, ubiquitinated by ER-resident ligases, and fed to the proteasome -- the cell's quality control for the secretory pathway, essential because the ER handles a third of all proteins. In immunity, a variant called the immunoproteasome -- with alternative catalytic subunits induced by interferon-gamma -- generates the peptide repertoire presented on MHC class I molecules, shaping which fragments the immune system sees; its cleavage preferences differ subtly, optimizing peptide production for antigen presentation. The proteasome also drives the cell cycle by destroying cyclins and securin at precisely timed moments, and regulates transcription by degrading transcription factors. It is less a garbage disposal than a control system: most of its substrates are destroyed not because they are damaged but because their time is up.
Blocking the shredder: therapeutics
Because cancer cells -- especially antibody-producing multiple myeloma cells -- live on the edge of proteotoxic stress, proteasome inhibition is selectively lethal to them. Bortezomib, the first-in-class drug, reversibly inhibits the chymotrypsin-like site of the 20S core; by blocking degradation, it causes misfolded proteins to accumulate, triggers the unfolded protein response, stabilizes pro-apoptotic factors, and inhibits NF-kB signaling (by preventing IkB degradation) -- a multi-pronged assault that transformed myeloma treatment. Newer inhibitors (carfilzomib, ixazomib) improved potency and administration. Resistance emerges through mutations in the targeted beta subunit, upregulation of proteasome subunits, and shifts toward alternative degradation routes like autophagy -- the cell's backup demolition system. The therapeutic logic extends beyond cancer: proteasome and DUB modulators are investigated in neurodegeneration, where failed clearance of aggregated proteins is central, though here the goal is activation rather than inhibition -- a reminder that the same machine can be dialed in either direction.
Most proteasome substrates are not damaged -- they are cyclins, transcription factors, and signaling proteins destroyed on schedule. The ubiquitin-proteasome system is a control system first and a waste system second.
Key points
- The 26S proteasome = 20S core (sequestered threonine proteases) + 19S regulators (ubiquitin receptors, AAA+ ATPases, deubiquitinases).
- K48 ubiquitin chains target substrates; 19S receptors bind them, DUBs strip ubiquitin, and ATPases unfold and thread the polypeptide into the chamber.
- Proteasomal DUBs (Rpn11, USP14, UCH37) provide kinetic proofreading -- chain trimming can rescue substrates before commitment.
- ERAD feeds misfolded secretory proteins to the proteasome; the immunoproteasome generates MHC class I peptides.
- Bortezomib and successors treat multiple myeloma by blocking the chymotrypsin-like site, exploiting cancer cells' proteotoxic stress.
Common misconceptions
✓ Truth: Most substrates are healthy proteins -- cyclins, transcription factors -- destroyed on schedule. It is a regulatory system first, a quality-control system second.
✓ Truth: Proteasomal deubiquitinases proofread: short chains or unfoldable substrates can be rescued by chain trimming before commitment.
✓ Truth: They exploit differential vulnerability -- myeloma cells' extreme protein load makes them selectively sensitive, which is why the drugs are therapeutic rather than merely toxic.
Frequently asked questions
What are the 20S and 19S particles?
The 20S core is a barrel of four stacked rings housing sequestered protease sites; the 19S regulatory particle caps the ends, recognizing ubiquitin chains, removing them, and unfolding substrates with AAA+ ATPases.
How does the proteasome avoid destroying everything?
Active sites are sealed inside the 20S chamber, whose narrow gated entry admits only unfolded polypeptides delivered by the 19S -- destruction requires ubiquitin tagging plus mechanical unfolding.
What do proteasomal deubiquitinases do?
Rpn11 strips chains en bloc during translocation; USP14 and UCH37 trim chains and can rescue substrates -- kinetic proofreading that filters which ubiquitinated proteins are actually degraded.
What is ERAD?
ER-associated degradation: misfolded secretory proteins are retrotranslocated from the ER to the cytosol, ubiquitinated, and degraded by the proteasome -- quality control for the secretory pathway.
Why do proteasome inhibitors treat myeloma?
Myeloma cells produce enormous antibody loads and live near proteotoxic collapse; blocking the proteasome pushes them over the edge while sparing less-stressed cells.